5 pending office actions
| App # | Title | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|
| 18573359 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS | SAMSELL, RILLA MARIE | 1624 | Non-Final OA | Dec 21, 2023 |
| 18273710 | NALTREXONE COMPOSITIONS | ARNOLD, ERNST V | 1613 | Final Rejection | Jul 21, 2023 |
| 18330163 | ASSAY TO IDENTIFY ANTI-CANCER AGENTS | HOWELL, THEODORE R | 1628 | Non-Final OA | Jun 06, 2023 |
| 17437724 | CANCER TREATMENT COMPRISING NALTREXONE AND A CANNABINOID | MAHLUM, JONATHAN DAVIS | 1625 | Final Rejection | Sep 09, 2021 |
| 17435911 | METHOD FOR DETERMINING EFFICACY | MOSS, NATALIE M | 1653 | Final Rejection | Sep 02, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial